

Date: 6th May, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Audited Financial Results for the quarter and Financial Year ended 31st March, 2025.

With reference to the captioned subject, please find enclosed herewith Press Release on the Audited Financial Results for the quarter and financial year ended 31st March, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Press Release

Alembic Pharmaceuticals Ltd announces financial results for Q4 2025

Net Revenue up 17%

Profit Before Tax at Rs. 192 Cr.

Vadodara, May 6th, 2025

Alembic Pharmaceuticals Limited reported its consolidated financial results for the fourth quarter ended 31st March, 2025.

Financial Highlights

- Net Sales increased by 17% to Rs.1770 Cr.
- EBITDA up by 9% to Rs. 286 Cr.
- EBITDA Margin at 16% of Sales
- Profit Before Tax up by 5% to Rs.192 Cr.
- Net Profit at Rs.157 Cr.

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited, said, “India-Branded Business displayed improved performance, backed by Specialty therapies. While the Animal Health division continued to outperform through a strong portfolio of trusted brands. By deepening our engagement with healthcare professionals and expanding our product pipeline, we have laid a solid foundation for strong, consistent growth, going forward. Our Ex-US business delivered a strong growth of 43% across all markets whereas the US business grew by 20% during the quarter.”

Operational Highlights

India Branded Business

- India Branded Business grew by 8% to Rs. 545 Cr. for the quarter.
- Gynaecology, Anti Diabetic, Ophthalmology and Dermatology therapy witnessed healthy growth for the quarter.
- Anti-infective segment and Cough & Cold segment grew by 7% and 11% for the quarter.
- 4 launches during the quarter and 14 launches during the year. New launches continue to do well along with promising future launches across key segments.
- Animal Health business grew by 19% for the quarter. Basket of strong brands continue to drive outperformance.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

International Business

- US Generics grew by 20% to Rs. 508 Cr. for the quarter.
- 4 Launches in the US market during the quarter.
- Ex-US International Generics grew by 43% to Rs. 375 Cr. for the quarter.
- 2 ANDA approvals received during the quarter, 220 Cumulative ANDA approvals.

API Business

- API business grew by 4% to Rs. 342 Cr. for the quarter.

The summary of Total Revenue is as under:

(Rs in Cr.)

Particulars	Q4 FY25	Q4 FY24	% Change	FY25	FY24	% Change
Formulation						
India	545	503	8%	2339	2200	6%
USA	508	423	20%	1957	1730	13%
Ex- US	375	262	43%	1243	1052	18%
API	342	330	4%	1133	1246	(9%)
Total	1770	1517	17%	6672	6229	7%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5500 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information, contact:

Ajay Kumar Desai

Phone: +91 022- 66953681 Email: ajay.desai@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123